Applied DNA Sciences Q3 EPS $(0.24), Inline, Sales $2.92M Beat $2.56M Estimate
Portfolio Pulse from Benzinga Newsdesk
Applied DNA Sciences (NASDAQ:APDN) reported Q3 losses of $(0.24) per share, in line with analyst consensus. This is an 84.62% decrease from the same period last year. The company's quarterly sales of $2.92M beat the analyst consensus of $2.56M by 13.95%, but this is a 32.10% decrease from last year's sales.
August 10, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Applied DNA Sciences reported Q3 losses in line with estimates, but sales beat expectations. However, both earnings and sales are down significantly YoY.
While APDN's Q3 losses were in line with estimates and sales beat expectations, the significant YoY decreases in both earnings and sales could negatively impact investor sentiment and the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100